Boundless Bio, Inc. (BOLD) received an amended Schedule 13G/A indicating that former reporting holders now report zero ownership of its common stock as of December 31, 2025. Nextech VI Oncology SCSp, Nextech VI GP S.a. r.l., Ian Charoub, Costas Constantinides and Rocco Sgobbo each report beneficial ownership of 0 shares, representing 0.0% of the common stock.
The filers state that they own 5 percent or less of the class and certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of Boundless Bio, and are not held in connection with any control-related transaction.
Positive
None.
Negative
None.
Insights
Former large holders now report no Boundless Bio stake.
The filing shows Nextech VI Oncology, its general partner and related individuals now report owning 0 shares, or 0.0% of Boundless Bio common stock as of December 31, 2025. This signals that a prior institutional-style holder no longer has a reportable equity position.
The filers also affirm ownership of 5 percent or less of the class and certify the position is not held to change or influence control. The information mainly affects the company’s shareholder mix rather than its operations or finances, so the impact is primarily on who holds the stock, not on business fundamentals.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
BOUNDLESS BIO, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
10170A100
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
10170A100
1
Names of Reporting Persons
Nextech VI GP S.a. r.l.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
LUXEMBOURG
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
10170A100
1
Names of Reporting Persons
Nextech VI Oncology SCSp
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
LUXEMBOURG
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
10170A100
1
Names of Reporting Persons
Ian Charoub
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWEDEN
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
10170A100
1
Names of Reporting Persons
Costas Constantinides
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CYPRUS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
10170A100
1
Names of Reporting Persons
Rocco Sgobbo
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BOUNDLESS BIO, INC.
(b)
Address of issuer's principal executive offices:
9880 Campus Point Drive, Suite 120, San Diego, CA, 92121.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
Nextech VI Oncology SCSp ("Nextech VI LP")
Nextech VI GP S.a. r.l. ("Nextech VI GP")
Ian Charoub ("Charoub")
Costas Constantinides ("Constantinides")
Rocco Sgobbo ("Sgobbo")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
(b)
Address or principal business office or, if none, residence:
8 rue Lou Hemmer
L-1748 Luxembourg-Findel
Grand-Duche de Luxembourg
(c)
Citizenship:
Nextech VI LP Luxembourg
Nextech VI GP Luxembourg
Charoub Sweden
Constantinides Cyprus
Sgobbo Switzerland
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
10170A100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Nextech VI GP S.a. r.l.
Signature:
/s/ Ian Charoub
Name/Title:
By Ian Charoub, Manager
Date:
02/17/2026
Signature:
/s/ Costas Constantinides
Name/Title:
By Costas Constantinides, Manager
Date:
02/17/2026
Nextech VI Oncology SCSp
Signature:
/s/ Ian Charoub
Name/Title:
By Nextech VI GP S.a. r.l., its General Partner, By Ian Charoub, Manager
Date:
02/17/2026
Signature:
/s/ Costas Constantinides
Name/Title:
By Nextech VI GP S.a. r.l., its General Partner, By Costas Constantinides, Manager
Date:
02/17/2026
Ian Charoub
Signature:
/s/ Ian Charoub
Name/Title:
Ian Charoub
Date:
02/17/2026
Costas Constantinides
Signature:
/s/ Costas Constantinides
Name/Title:
Costas Constantinides
Date:
02/17/2026
Rocco Sgobbo
Signature:
/s/ Rocco Sgobbo
Name/Title:
Rocco Sgobbo
Date:
02/17/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons with the SEC on April 12, 2024).
What does Boundless Bio (BOLD) disclose in this Schedule 13G/A amendment?
The amendment shows several prior reporting holders now report owning 0 shares, or 0.0%, of Boundless Bio common stock as of December 31, 2025. It updates their beneficial ownership status for regulatory transparency.
Who are the reporting persons in the Boundless Bio (BOLD) Schedule 13G/A?
The reporting persons are Nextech VI Oncology SCSp, Nextech VI GP S.a. r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo. Together they are referenced as the Reporting Persons but expressly disclaim status as a “group.”
How many Boundless Bio (BOLD) shares do the reporting persons now own?
Each reporting person lists beneficial ownership of 0.00 shares of Boundless Bio common stock, representing 0.0% of the class, as of December 31, 2025. Their cover pages uniformly reflect zero voting and dispositive power.
What does “ownership of 5 percent or less” mean in the Boundless Bio filing?
Item 5 states ownership of 5 percent or less of Boundless Bio’s common stock. In this amendment, each reporting person actually reports 0 shares and 0.0% of the class, confirming they no longer have a reportable stake.
Are the Boundless Bio (BOLD) reporting persons seeking to influence control of the company?
No. They certify the securities referenced were not acquired and are not held to change or influence control of Boundless Bio, nor in connection with any transaction having that purpose, other than activities related to a nomination under Rule 14a-11.
What security is covered in this Boundless Bio Schedule 13G/A amendment?
The filing covers Boundless Bio, Inc. common stock with a par value of $0.0001 per share, identified by CUSIP 10170A100. It updates beneficial ownership information for that specific class of equity securities.
